Adagio Medical Holdings, Inc.
ADGM Healthcare Medical Devices
Adagio Medical Holdings, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $602,000.00, up 100.7% from fiscal 2023. In the quarter to June 2026, revenue fell 33.5%, EPS fell 15.4%, free cash flow fell 12.9% and total debt rose 46.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ADGM
Adagio Medical Holdings, Inc. (ADGM) EV/Sales
As of 16 October 2026, Adagio Medical Holdings, Inc. (ADGM) trades at a EV/Sales of 32.1×. Over the past ten years it has ranged from 0.0× (June 2024) to 87.7× (October 2025); the current reading is higher than 71% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 19.7× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | 19.7× | (45.62%) |
| Sep 2024 | 36.2× | 133.39% |
| Jun 2024 | 15.5× | — |
| Mar 2024 | 0.0× | — |
| 2 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ICCM IceCure Medical Ltd. compare | −3.4× |
| IVF INVO Fertility, Inc compare | −0.3× |
| BJDX Bluejay Diagnostics, Inc. compare | n/m |
| NUVOQ Holdco Nuvo Group D.G Ltd. compare | n/m |
| BIOLQ Biolase, Inc. compare | 0.3× |
| XAIR Beyond Air, Inc. compare | 1.1× |
| VJET Flyte Aviation, Inc. compare | 2.1× |
| NXL Nexalin Technology, Inc. compare | 3.0× |
| ADGM Adagio Medical Holdings, Inc. | 32.1× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)